Amyl Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.46M

  • Investors
  • 8

Amyl Therapeutics General Information

Description

Operator of biotechnology therapeutics intended to treat diseases caused by amyloid fibrils and misfolded proteins. The company offers a platform for developing therapies that target multiple misfolded proteins associated with neurodegenerative diseases, enabling healthcare providers to treat protein misfolding disorders and address the accumulation of protein aggregates in the brain.

Contact Information

Website
www.amyltx.com
Formerly Known As
Pierre Vandepapeliere & Florent Gros
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Boulevard Patience et Beaujonc 3, box 12
  • 4000 Liege
  • Belgium
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Boulevard Patience et Beaujonc 3, box 12
  • 4000 Liege
  • Belgium

Amyl Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amyl Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Sep-2026 $4.46M Completed Pre-Clinical Trials
3. Grant 01-Sep-2026 Completed Pre-Clinical Trials
2. Grant $8.78M $14.8M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 08-Nov-2023 $14.8M $14.8M Completed Pre-Clinical Trials
To view Amyl Therapeutics’s complete valuation and funding history, request access »

Amyl Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A2
Class A1
To view Amyl Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Amyl Therapeutics Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Amyl Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3806884-A1 General amyloid interaction motif (gaim) Active 15-Jun-2018
EP-3806884-B1 General amyloid interaction motif (gaim) Active 15-Jun-2018
EP-3806884-C0 General amyloid interaction motif (gaim) Active 15-Jun-2018
EP-4389154-A2 General amyloid interaction motif (gaim) Pending 15-Jun-2018
EP-4389154-A3 General amyloid interaction motif (gaim) Pending 15-Jun-2018 C07K14/4703
To view Amyl Therapeutics’s complete patent history, request access »

Amyl Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amyl Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
6K venture capital Venture Capital Minority
Carbon ( Belgium ) Venture Capital Minority
Angel (individual) Minority
JFG Life Sciences Foundation University Minority
Merieux Equity Partners (Lyon) PE/Buyout Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Amyl Therapeutics FAQs

  • When was Amyl Therapeutics founded?

    Amyl Therapeutics was founded in 2020.

  • Where is Amyl Therapeutics headquartered?

    Amyl Therapeutics is headquartered in Liege, Belgium.

  • What is the size of Amyl Therapeutics?

    Amyl Therapeutics has 12 total employees.

  • What industry is Amyl Therapeutics in?

    Amyl Therapeutics’s primary industry is Biotechnology.

  • Is Amyl Therapeutics a private or public company?

    Amyl Therapeutics is a Private company.

  • What is Amyl Therapeutics’s current revenue?

    The current revenue for Amyl Therapeutics is .

  • How much funding has Amyl Therapeutics raised over time?

    Amyl Therapeutics has raised $19.3M.

  • Who are Amyl Therapeutics’s investors?

    6K venture capital, Carbon ( Belgium ), , JFG Life Sciences Foundation, and Merieux Equity Partners (Lyon) are 5 of 8 investors who have invested in Amyl Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process